Results 191 to 200 of about 160,145 (308)

Blinatumomab for Pediatric High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia: Safety, MRD Response and Survival in a Single-Center Retrospective Cohort [Removal]. [PDF]

Immunotargets Ther
europepmc   +1 more source

Type B Lactic Acidosis and Acute Kidney Injury Heralding B-Lymphoblastic Leukemia/Lymphoma. [PDF]

Mediterr J Hematol Infect Dis
Su Z, Fan Q, Jiang Y.
europepmc   +1 more source

Development and Implementation of a Disease‐Targeted Storybook as a Clinical Tool for Children With Acute Leukemia

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
ABSTRACT Background Although significant progress has been made in childhood leukemia survival, healthcare providers, and caregivers often face challenges in explaining this disease to patients. Disease‐targeted storybooks have been proposed as a tool to facilitate the understanding of diagnoses and treatment.
Nutvipha Ummartyotin, Usanarat Anurathapan, Rawiwan Roongpraiwan, Potchanee Dandamrongrak, Siriporn Nakhonchai, Pawin Numthavaj, Vilawan Chirdkiatgumchai   +6 more
wiley   +1 more source

Occurrence of Extramedullary Relapses in Pediatric Acute Lymphoblastic Leukemia After Treatment With Blinatumomab

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
ABSTRACT We report a retrospective single‐center analysis of pediatric patients with relapsed or refractory B‐cell precursor acute lymphoblastic leukemia focusing on relapses outside of the typical locations, bone marrow, central nervous system, or testes.
Johanna Kunz, Martin Ebinger, Michaela Döring, Markus Mezger, Ursula Holzer, Rupert Handgretinger, Peter Lang, Manon Queudeville   +7 more
wiley   +1 more source

Medicine Requirements and Budget Implication for Pediatric Acute Lymphoblastic Leukemia in Indonesia: A Morbidity-Based Approach. [PDF]

Risk Manag Healthc Policy
Argadiredja DNS, Alfaqeeh M, Fatinah Y, Gatera VA, Andalusia LR, Sinuraya RK, Abushanab D, Abdulah R, Suwantika AA.   +8 more
europepmc   +1 more source

Cardiovascular Toxicity Associated With Bispecific Antibodies in Hematological Malignancies: A Comprehensive Pharmacovigilance Analysis

American Journal of Hematology, Volume 101, Issue 10, Page 2546-2556, October 2026.
ABSTRACT Cardiovascular adverse events (CVAEs) associated with bispecific T‐cell engaging antibodies (BsAbs) have not been systematically investigated across approved agents. In this disproportionality analysis of FAERS (December 2014–September 2025), reports listing BsAbs as the primary suspected drug (n = 7647) were compared with all other drugs in ...
Malak Munir, Ahmed Sayed, Dae Hyun Lee, Sanam Ghazi, Mustafa M. Houmsse, Saad Badat, Abdul Moeed, Avirup Guha, Daniel Addison, Narendranath Epperla   +9 more
wiley   +1 more source

Spontaneous regression of B-cell acute lymphoblastic leukemia with PAX5 alterations at relapse: a case report. [PDF]

Ann Hematol
Lesan V, Bittenbring J, Altmeyer S.
europepmc   +1 more source

Model‐Based Analysis with Mechanistic Insights to CAR‐T‐Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1027-1040, October 2026.
Model‐informed drug development is increasingly used to support chimeric antigen receptor (CAR)‐T‐cell therapy programs. However, most population pharmacokinetic (PK) CAR‐T‐cell models available in literature are variations of an empirical piecewise‐linear model, which accurately describes the observed data but lacks a mechanistic foundation.
Anna M. Mc Laughlin, Martin Bergstrand, Ana Ruiz‐Garcia, Simone Filosto, Rhine Shen   +4 more
wiley   +1 more source

Fatal Disseminated Fusariosis During Induction Therapy for Adult Acute Lymphoblastic Leukemia in a Patient with Prior Multiple Myeloma. [PDF]

Mediterr J Hematol Infect Dis
Alberti S, Cavallaro G, Tebaldi A, Tebaldi P, Finazzi MC, Grassi A, Galli M, Paris L, Stefanoni P, Valsecchi F, Rambaldi A, Lussana F.   +11 more
europepmc   +1 more source

The 9th Edition of the UICC TNM Classification of Malignant Tumours: Updates and Rationale for Change

International Journal of Cancer, Volume 159, Issue 7, Page 1588-1601, 1 October 2026.
ABSTRACT The standard for assessing and recording the extent of the tumour, a necessity for most malignancies, is the Tumour Node Metastases (TNM) classification. The Union for International Cancer Control (UICC) TNM committee has defined this since the early 1950s.
James D. Brierley, Liesbet J. Van Eycken, Meredith E. Giuliani, Brian A. Rous, Shao Hui Huang, Hisao Asamura, Mary K. Gospodarowicz, Anne W. Lee, Brian O'Sullivan   +8 more
wiley   +1 more source